In a set of newly released presentations, officials from the US Food and Drug Administration (FDA) explain changes to the agency's biomarker qualification program and detail early opportunities for ...

Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...

ViewsML, a company building the computational layer for biomarker discovery by transforming tissue analysis from a lab process into software, today announced the completion of an oversubscribed $4.9M ...

Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...

Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...

SAN DIEGO & TOKYO & MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

Key market opportunities in the CNS Biomarkers sector include utilizing AI and technologies like ML and NLP to enhance drug ...

Panome Bio, a CRO, launched MassID™, a cloud-based computational platform designed to improve how researchers process and interpret untargeted LC/MS metabolomics data. The platform is described in a ...

Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer The CHAI platform extracted ...